Krystal Biotech, Inc., a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in preclinical development to treat dystrophic epidermolysis bullosa, a genetic disease. It also engages in developing KB105, which is in preclinical studies to treat Lamellar Ichthyosis, which is an autosomal recessive disorder. The company was formerly known as Krystal Biotech, LLC and changed its name to Krystal Biotech, Inc. in March 2017. Krystal Biotech, Inc. was founded in 2015 and is based in Pittsburgh, Pennsylvania.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KRYS
Previous Symbol
CUSIPN/A
Phone412-586-5830
Debt
Debt-to-Equity RatioN/A
Current Ratio27.65
Quick Ratio27.65
Price-To-Earnings
Trailing P/E Ratio-16.07
Forward P/E Ratio-25.04
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$4.83 per share
Price / Book4.93
Profitability
EPS (Most Recent Fiscal Year)($1.48)
Net Income$-7,920,000.00
Net MarginsN/A
Return on Equity-17.92%
Return on Assets-17.56%
Miscellaneous
Employees12
Outstanding Shares14,430,000
Market Cap$338.93 million
OptionableNot Optionable
Krystal Biotech (NASDAQ:KRYS) Frequently Asked Questions
What is Krystal Biotech's stock symbol?
Krystal Biotech trades on the NASDAQ under the ticker symbol "KRYS."
How were Krystal Biotech's earnings last quarter?
Krystal Biotech Inc (NASDAQ:KRYS) announced its quarterly earnings data on Monday, November, 5th. The company reported ($0.26) EPS for the quarter, meeting the consensus estimate of ($0.26). View Krystal Biotech's Earnings History.
When is Krystal Biotech's next earnings date?
What price target have analysts set for KRYS?
6 analysts have issued twelve-month price objectives for Krystal Biotech's stock. Their predictions range from $32.00 to $38.00. On average, they anticipate Krystal Biotech's stock price to reach $35.00 in the next year. This suggests a possible upside of 47.1% from the stock's current price. View Analyst Price Targets for Krystal Biotech.
What is the consensus analysts' recommendation for Krystal Biotech?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Krystal Biotech in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Krystal Biotech.
What are Wall Street analysts saying about Krystal Biotech stock?
Here are some recent quotes from research analysts about Krystal Biotech stock:
- 1. According to Zacks Investment Research, "Krystal Biotech, Inc. is a gene therapy company. It engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. Krystal Biotech, Inc. is based in Pittsburgh, United States. " (12/11/2018)
- 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating though are lowering our price target to $32 from $35.50. The driver to our valuation change include: (1) adjustment to base year; (2) adjustment to fully diluted share count off of October 2018 equity raise; and (3) adjusting our applied P/E multiple from 14.5x to 17.0x, which is our standard multiple in our coverage universe. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile." (11/5/2018)
- 3. Cantor Fitzgerald analysts commented, ": We are reiterating our Overweight rating and increasing our price target to $35/share from $28/share on Krystal Biotech. This morning, Krystal announced and held a conference call to discuss interim results from two patients in the ongoing Phase 1/2 study (GEM) of KB103 for the treatment of dystrophic epidermolysis bullosa (DEB). The trial met all primary efficacy endpoints for the two patients and showed substantial improvements in time to wound closure, in our view. Importantly, KB103 was well tolerated with no serious adverse events or product- related adverse events reported. Krystal remains on track to complete the study in 1H19." (10/15/2018)
Has Krystal Biotech been receiving favorable news coverage?
Headlines about KRYS stock have trended somewhat positive this week, InfoTrie reports. The research group identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Krystal Biotech earned a coverage optimism score of 1.0 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
Who are some of Krystal Biotech's key competitors?
Some companies that are related to Krystal Biotech include Orchard Therapeutics (ORTX), Sangamo Therapeutics (SGMO), Momenta Pharmaceuticals (MNTA), Iovance Biotherapeutics (IOVA), Fate Therapeutics (FATE), Audentes Therapeutics (BOLD), BioCryst Pharmaceuticals (BCRX), Solid Biosciences (SLDB), Acorda Therapeutics (ACOR), Gritstone Oncology (GRTS), Cellectis (CLLS), DBV TECHNOLOGIE/S (DBVT), Novavax (NVAX), Twist Bioscience (TWST) and Heska (HSKA).
Who are Krystal Biotech's key executives?
Krystal Biotech's management team includes the folowing people:
- Mr. Krish S. Krishnan, Pres, CEO & Chairman (Age 53)
- Ms. Suma M. Krishnan, Founder, COO & Director (Age 53)
- Ms. Pooja Agarwal, VP of Product Devel. (Age 39)
- Mr. Antony A. Riley, Chief Financial Officer (Age 51)
When did Krystal Biotech IPO?
(KRYS) raised $30 million in an initial public offering on Wednesday, September 20th 2017. The company issued 3,000,000 shares at $9.00-$11.00 per share. Ladenburg Thalmann acted as the underwriter for the IPO.
Who are Krystal Biotech's major shareholders?
Krystal Biotech's stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (6.48%), Vanguard Group Inc. (1.20%), Baker BROS. Advisors LP (0.79%), S Squared Technology LLC (0.37%), Renaissance Technologies LLC (0.35%) and JPMorgan Chase & Co. (0.33%). Company insiders that own Krystal Biotech stock include Antony A Riley, Daniel Janney, Krish S Krishnan, R Douglas Norby and Suma Krishnan. View Institutional Ownership Trends for Krystal Biotech.
Which major investors are selling Krystal Biotech stock?
Which major investors are buying Krystal Biotech stock?
KRYS stock was bought by a variety of institutional investors in the last quarter, including S Squared Technology LLC, Renaissance Technologies LLC, P.A.W. Capital Corp, Vanguard Group Inc., JPMorgan Chase & Co. and Acadian Asset Management LLC. Company insiders that have bought Krystal Biotech stock in the last two years include Antony A Riley, Daniel Janney, Krish S Krishnan, R Douglas Norby and Suma Krishnan. View Insider Buying and Selling for Krystal Biotech.
How do I buy shares of Krystal Biotech?
Shares of KRYS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Krystal Biotech's stock price today?
One share of KRYS stock can currently be purchased for approximately $23.79.
How big of a company is Krystal Biotech?
Krystal Biotech has a market capitalization of $338.93 million. The company earns $-7,920,000.00 in net income (profit) each year or ($1.48) on an earnings per share basis. Krystal Biotech employs 12 workers across the globe.
What is Krystal Biotech's official website?
How can I contact Krystal Biotech?
Krystal Biotech's mailing address is 2100 WHARTON STREET SUITE 701, PITTSBURGH PA, 15203. The company can be reached via phone at 412-586-5830.
MarketBeat Community Rating for Krystal Biotech (NASDAQ KRYS)
MarketBeat's community ratings are surveys of what our community members think about Krystal Biotech and other stocks. Vote "Outperform" if you believe KRYS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KRYS will underperform the S&P 500 over the long term. You may vote once every thirty days.
